NKG2D ligands: unconventional MHC class I-like molecules exploited by viruses and cancer
- PMID: 12753652
- DOI: 10.1034/j.1399-0039.2003.00070.x
NKG2D ligands: unconventional MHC class I-like molecules exploited by viruses and cancer
Abstract
Our best teachers in revealing the importance of immune pathways are viruses and cancers that have subverted the most prominent pathways to escape from immune recognition. Viruses and cancer impair antigen presentation by classical MHC class I to escape adaptive immunity. The activating receptor NKG2D and its MHC class I-like ligands are other recently defined innate and adaptive immune pathways exploited by viruses and cancer. This review discusses recent advances in the understanding of how NKG2D, expressed on innate immune cells including natural killer cells, gammadelta+ T cells and macrophages, and adaptive immune cells such as CD8+ T cells, recognize stress-induced, MHC class I-like, self-ligands. Moreover, we describe how viruses and cancer have developed strategies to evade this recognition pathway.
Similar articles
-
Strategies for target cell recognition by natural killer cells.Immunol Rev. 2001 Jun;181:170-84. doi: 10.1034/j.1600-065x.2001.1810114.x. Immunol Rev. 2001. PMID: 11513138 Review.
-
Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA.Science. 1999 Jul 30;285(5428):727-9. doi: 10.1126/science.285.5428.727. Science. 1999. PMID: 10426993
-
A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity.Eur J Immunol. 2003 Feb;33(2):381-91. doi: 10.1002/immu.200310012. Eur J Immunol. 2003. PMID: 12645935
-
The UL16-binding proteins, a novel family of MHC class I-related ligands for NKG2D, activate natural killer cell functions.Immunol Rev. 2001 Jun;181:185-92. doi: 10.1034/j.1600-065x.2001.1810115.x. Immunol Rev. 2001. PMID: 11513139 Review.
-
The innate immune response to tumors and its role in the induction of T-cell immunity.Immunol Rev. 2002 Oct;188:9-21. doi: 10.1034/j.1600-065x.2002.18802.x. Immunol Rev. 2002. PMID: 12445277 Review.
Cited by
-
The efficacy and applicability of chimeric antigen receptor (CAR) T cell-based regimens for primary bone tumors: A comprehensive review of current evidence.J Bone Oncol. 2024 Sep 22;48:100635. doi: 10.1016/j.jbo.2024.100635. eCollection 2024 Oct. J Bone Oncol. 2024. PMID: 39381633 Free PMC article. Review.
-
CAR-T cell immunotherapy for ovarian cancer: hushing the silent killer.Front Immunol. 2023 Dec 7;14:1302307. doi: 10.3389/fimmu.2023.1302307. eCollection 2023. Front Immunol. 2023. PMID: 38146364 Free PMC article. Review.
-
NK cells and psoriasis.J Biomed Biotechnol. 2011;2011:248317. doi: 10.1155/2011/248317. Epub 2011 May 26. J Biomed Biotechnol. 2011. PMID: 21687543 Free PMC article. Review.
-
Natural Killer Cells as Key Mediators in Type I Diabetes Immunopathology.Front Immunol. 2021 Aug 20;12:722979. doi: 10.3389/fimmu.2021.722979. eCollection 2021. Front Immunol. 2021. PMID: 34489972 Free PMC article. Review.
-
Glycosylation contributes to variability in expression of murine cytomegalovirus m157 and enhances stability of interaction with the NK-cell receptor Ly49H.Eur J Immunol. 2010 Sep;40(9):2618-31. doi: 10.1002/eji.200940134. Eur J Immunol. 2010. PMID: 20662096 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials